New Cancer Drug: 200 Times More Effective Killing Tumors

March 28, 2009

(ChattahBox)—A global team of cancer researchers published an exciting new study in the Journal of the American Chemical Society this week, showing that zoledronate, a new type of bisphosphonate drug, when combined with hormone therapy, reduced the recurrence of breast cancer in pre-menopausal women at a significant rate. Researchers found this new drug agent is nearly 200 times more powerful at killing cancer cells than previous drugs. This is astounding news for the nearly 200,00 women and men diagnosed with breast cancer every year, and the nearly 50,000 that lose their battle with the disease.

Researchers found that the new drug, zoledronat, since it comes from a class of drugs known as bisphosphonates, has powerful anti-cancer and immune boosting properties. Bisphosphonates were previously used to treat osteoporosis and other diseases of the bone. Zoledronant works by attacking enzymes, named FPPS and GGPPS, which are located in the cell survival pathway. Once the pathways are blocked, the cancer cells die off. They essentially reach a dead end and can no longer multiply.

This new drug differs from previous unsuccessful treatments that attacked a protein called Ras in the cell pathways. Since nearly a third of human cancers are caused from a mutated Ras gene, researchers theorized a drug attacking the gene would kill cancer cells, but it didn’t work.

This new drug, Zoledronant works a few blocks away from the Ras cell survival pathway. It’s showing great success in inhibiting the pathways, and killing the lethal cancer cells in pre-menopausal women with estrogen-receptor-positive breast cancer. Previous studies have shown success in treating men with hormone-refractory prostate cancer, as well.

Researchers now plan to continue and expand their Zoledronant clinical trials, and are back in their labs working on new Bisphosphonate drug compounds that may even be more effective. Bisphosphonates are known to attach to bone, which is why they are so effective for treating osteoporosis.

The researchers are having success in developing new compounds that bind to enzymes, but not to bone. A new compound called BPH-715, killed tumor cells in mice and didn’t bind to the bone. Both zoledronate and BPH-715 were found to set off the production of gamma delta T, immune cells, which help to kill tumor cells in humans.

This international team of researchers led by US researchers from the University of Illinois, including scientists from Europe, Taiwan and Japan are at the forefront of promising new cancer treatments.

Source


Comments

2 Responses to “New Cancer Drug: 200 Times More Effective Killing Tumors”

  1. New Cancer Drug: 200 Times More Effective Killing Tumors : ChattahBox | Life Sciences Blog on March 29th, 2009 5:32 am

    […] from Europe, Taiwan and Japan are at the forefront of promising new cancer treatments….Read the Full Story VN:F [1.1.8_518]please wait…Rating: 0.0/10 (0 votes […]

  2. New Cancer Drug: 200 Times More Effective Killing Tumors : ChattahBox | OncoBlog on March 29th, 2009 3:03 pm

    […] original here:  New Cancer Drug: 200 Times More Effective Killing Tumors : ChattahBoxRelated Posts No Related […]

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.